Gonadotropin-releasing hormone analogues for dysfunctional bleeding in women after liver transplantation: a new application.
A new clinical indication for GnRH agonists treatment seems to exist in addition to the many indications known so far (4, 5). These previously mentioned indications include: uterine fibroids, precocious puberty, endometriosis, polycystic ovarian disease, ovulation induction for assisted fertilization (in vitro or in vivo), treatment of various tumors such as prostatic, breast, pancreatic, ovarian, and pituitary tumors, and various catamenial disorders such as premenstrual syndrome and porphyria. Women after liver transplantation, who are in the reproductive age and who experience menometrorrhagia or dysfunctional bleeding, seem to be a new indication for application of these useful GnRH analogues. This application may prevent the potential hepatotoxicity or cholestasis of E-P combinations usually used for treatment of dysfunctional bleeding. The recommended treatment is of relatively short duration (3 to 6 months), within the first 2 years of the transplantation, after which a more prolonged treatment should be considered. This treatment may also spare the need for contraception during its administration because both oral contraceptives and intrauterine device are relatively contraindicated in these patients (the latter because of the immunocompromised state). We believe this application to become more common because of increasing numbers of liver transplantations and improved survival rate. It may be looked at as a "new application of a relatively new drug for a new and enlarging situation."
Blumenfeld
Z
Z
Department of Obstetrics and Gynecology, Ramban Medical Center, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Enat
R
R
Brandes
J M
JM
Baruch
Y
Y
D000328:Adult; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016031:Liver Transplantation; D008598:Menstruation; D011183:Postoperative Complications; D017329:Triptorelin Pamoate; D014592:Uterine Hemorrhage / Q000188:drug therapy* / Q000209:etiology
D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone